Ciphergen has signed a collaborative research agreement with Sanofi-Aventis, extending its existing relationship. The project will concentrate on discovery, validation, and identification of biomarkers for a preclinical drug efficacy study in the field of oncology. Under the terms of the agreement, Ciphergen will analyze samples at one of its Biomarker Discovery Center laboratories using its suite of proteomic solutions. Financial terms were not disclosed. “We are extremely pleased to ...